 |
BEIJING, May 7, 2026 /PRNewswire/ — Spirit AI (千寻智能) and Bosch China have formed a strategic alliance to industrialize the “Universal Brain” for robots. This partnership fuses Spirit AI’s leading VLA models with Bosch’s deep industrial ecosystem to bridge the gap between frontier embodied AI and large-scale industrial deployment.
Spirit AI x Bosch
Key Highlights of the Partnership:
- The Data Loop: Establishing a “Real-World Data — Embodied AI — Real-World Scenarios” pipeline within Bosch’s China-based factories and logistics centers.
- Hardware Synergy: Integration of Bosch’s mission-critical sensors and actuators to accelerate Spirit AI’s engineering validation and mass production.
- Embodied AI Model Iteration: Benchmarking Spirit v1.5 against global standards to ensure peak performance in complex, unstructured industrial tasks.
“This alliance marks our transition from technical excellence to industry leadership. Bosch’s industrial footprint across real-world scenarios, global supply chain, and channel resources will scale the reach of our ‘Universal Brain’ architecture.” — Han Fengtao (韩峰涛), Co-founder & CEO of Spirit AI
“Spirit AI has demonstrated leading technical prowess in the field of embodied AI models,” stated Liu Min, VP of Strategic Development at Bosch China and Head of the Bosch China Robotics Center. “Our collaboration will establish a new ecosystem paradigm for the robotics industry.”
About Spirit AI
Founded in 2024, Spirit AI is dedicated to developing “universal brains” for robots to create the next generation of intelligent workforce. By deploying general-purpose embodied models, the company provides robots with the robust generalization and physical precision required for the real world. Spirit AI is moving beyond the lab to integrate versatile robotic agents into the modern workforce, accelerating the arrival of real-world embodied AI.
Contact: [email protected]
ข่าวที่เกี่ยวข้อง
- AI: Digital to Physical | BEYOND Expo 2026 Leads Transformative Global Direction of Tech
- Golden Goblet Competition Lineup Announced: Spotlight on the 2026 Contenders
- Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
- Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
